Table 2

Demography and clinical features at anti-VEGF initiation for the model population

MARINA
sham-arm
(n=238)
MEH
matched
(n=215)
MEH
not matched
(n=110)
UHB
matched
(n=44)
UHB
not matched
(n=7)
Patient demography
Sex n (%)
 Female159 (66.8)128 (59.5)73 (66.4)32 (72.7)7 (100.0)
 Male79 (33.2)87 (40.5)37 (33.6)12 (27.3)0 (0.0)
Age (years) n (%)
 <6511 (4.6)9 (4.2)6 (5.5)2 (4.5)0 (0.0)
 65–6917 (7.1)19 (8.8)4 (3.6)1 (2.3)0 (0.0)
 70–7450 (21.0)37 (17.2)14 (12.7)4 (9.1)0 (0.0)
 75~7968 (28.6)58 (27.0)13 (11.8)4 (9.1)0 (0.0)
 80~8464 (26.9)60 (27.9)20 (18.2)19 (43.2)0 (0.0)
85+26 (10.9)32 (14.9)53 (48.2)14 (31.8)7 (100.0)
Ethnicity n (%)
 White231 (97.1)97 (45.1)55 (50.0)39 (88.6)6 (85.7)
 Not white7 (2.9)118 (54.9)55 (50.0)5 (11.4)1 (14.3)
Smoking status n (%)
 Yes130 (54.6)110 (51.2)55 (50.0)33 (75.0)3 (42.9)
 No or unknown108 (45.4)105 (48.8)55 (50.0)11 (25.0)4 (57.1)
Clinical features
Visual acuity (VA)
(ETDRS letters)
 Mean (SD)53.61 (14.06)52.92 (14.45)59.50 (18.36)52.55 (15.98)40.57 (20.98)
 Median (min, max)56.0 (3.0, 84.0)55.0 (0, 86.0)70.0 (11.0, 85.0)55.0 (0, 76.0)35.0 (11.0, 80.0)
VA ≥70 ETDRS letters n (%)
 Yes22 (9.2)16 (7.4)61 (55.5)8 (18.2)1 (14.3)
 No216 (90.8)199 (92.6)49 (44.5)36 (81.8)6 (85.7)
VA ≤20 ETDRS letters n (%)
 Yes4 (1.7)3 (1.4)3 (2.7)1 (2.3)1 (14.3)
 No234 (98.3)212 (98.6)107 (97.3)43 (97.7)6 (85.7)
VA <25 ETDRS letters n (%)
 Yes9 (3.8)12 (5.6)7 (6.4)1 (2.3)1 (14.3)
 No229 (96.2)203 (94.4)103 (93.6)43 (97.7)6 (85.7)
  • Patient characteristics and clinical features for the MARINA sham-control cohort as well as the forecasted patients for the matched and non-matched MEH and UHB cohorts are shown.

  • MARINA, Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD; MEH, Moorfields Eye Hospital; UHB, University Hospitals Birmingham; VEGF, vascular endothelial growth factor.